Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antagomir-miR-378a nanoparticle
- Development stage
- Preclinical
- Lead developer
- Queen's University Belfast
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Parenteral
01
Overview
Antagomir-miR-378a nanoparticle is an experimental RNA-based therapeutic consisting of an antagomir (a chemically modified antisense oligonucleotide) targeting microRNA-378a (miR-378a), encapsulated within a nanoparticle delivery system. miR-378a is a key regulator of metabolic inflammation and lipoprotein metabolism; its upregulation suppresses the estrogen-related receptor gamma (ERRγ) axis and genes involved in fatty acid β-oxidation (FAO) such as PPARα and CPT1α. By silencing miR-378a, the nanoparticle restores ERRγ signaling, enhances mitochondrial FAO, and improves high-density lipoprotein (HDL) metabolism (via LXRα and ABCA1), thereby reducing atherogenic VLDL secretion and metabolic inflammation. This approach is being investigated as a potential therapeutic strategy for atherosclerosis and related metabolic disorders.
- Other names
- antagomir-378a nanoparticleantagomir378a nanoparticleantagomir 378a nanoparticlemiR-378a antagomir nanoparticlemiR378a antagomir nanoparticlemiR 378a antagomir nanoparticle
02
Targets
ESRRG (Estrogen-related receptor gamma)
Beyond the preview
Go deeper on antagomir-miR-378a nanoparticle.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antagomir-miR-378a nanoparticle.